Acute lymphoblastic leukemia (ALL) cases with e13a3 fusion transcripts are extremely rare. We report a 24-year-old male with Ph-positive (Ph+) ALL with an aberrant e13a3 fusion transcript treated with CD19-specific chimeric antigen receptor T-cell (CAR-T) therapy. He developed refractory disease post-chemotherapy induction, andreceived allogeneic hematopoietic stem cell transplantation (allo-HSCT) after salvage with imatinib in combination with chemotherapy regimen. Unfortunately, the patient relapsed after +90 days post-transplant. He was consented to CAR-T therapy trial and achieved complete remission, highlighting the efficacy of CAR-T treatment in relapsed-refractory B-ALL irrespective of the underlying genetic drivers in leukemia cells .

带有e13a3融合转录本的急性淋巴细胞白血病（ALL）病例极为罕见。我们报告了一名24岁男性，患有Ph阳性（Ph +）ALL，并有异常的e13a3融合转录本经过CD19特异性嵌合抗原受体T细胞（CAR-T）治疗。他在化疗后诱发了难治性疾病，并在接受伊马替尼联合化疗方案的救治后接受了异基因造血干细胞移植（allo-HSCT）。不幸的是，患者在移植后90天后复发。他被同意接受CAR-T治疗试验并获得了完全缓解，从而突出了CAR-T治疗在复发性难治性B-ALL中的有效性，而与白血病细胞中潜在的遗传驱动因素无关。